Drugs / Trevogrumab
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02943239 | Dec 2016 → Apr 2019 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02741739 | Mar → Apr 2016 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01910220 | Aug 2013 → Jun 2014 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01720576 | Oct 2012 → Jun 2013 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01507402 | Jan → Nov 2012 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06299098 | Mar 2024 → May 2026 overdue | obesity disorder | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03710941 | Feb 2019 → Aug 2020 | inclusion body myositis | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01963598 | Nov 2013 → Jan 2015 | muscular atrophy | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trevogrumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06299098 ↗ |
| Known as | Human igg4 anti-myostatin mab | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545374 ↗ |
| Known as | REGN1033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01963598 ↗ |
| Known as | SAR391786 | “This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of Intravenous (IV) and Subcutaneous (SC)...” NCT01507402 ↗3“This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in...” NCT01963598 ↗ “subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.” NCT01720576 ↗ “Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)” NCT01910220 ↗ |
| Action | Inhibit | “Growth/differentiation factor 8 inhibitor” CHEMBL3545374 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3545374 ↗ |
| Route | Intravenous | “Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786)” NCT01507402 ↗ |
| Route | Subcutaneous | “Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786)” NCT01507402 ↗ |
| Target | MSTN | “Growth/differentiation factor 8 inhibitor” CHEMBL3545374 ↗ |